Urogen Pharma Shares Drop 4.5% as Analysts Weigh In

The biopharmaceutical company's stock price declines amid mixed analyst ratings and price targets.

Apr. 13, 2026 at 6:39pm

Got story updates? Submit your updates here. ›

An extreme close-up of complex financial machinery and equipment, conveying a sense of the heavy, tangible nature of banking and finance without using literal currency or charts.Urogen Pharma's stock price volatility reflects the uncertainties inherent in the biotech industry as the company navigates drug development and regulatory milestones.NYC Today

Shares of Urogen Pharma (NASDAQ:URGN) fell 4.5% during Monday's trading session, closing at $20.59. The drop came as the company's stock experienced a decline in trading volume, down 76% from its average daily volume. Several equity analysts have recently issued reports on Urogen Pharma, with a mix of buy and sell ratings and price targets ranging from $20 to $40.

Why it matters

Urogen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. The company's stock performance and analyst sentiment can provide insights into the market's perception of its product pipeline and commercial potential.

The details

The decline in Urogen Pharma's stock price on Monday came amid a broader market downturn. Analysts have issued a range of ratings and price targets for the company's stock, with some expressing optimism about its product pipeline and others voicing concerns about its commercial prospects.

  • Urogen Pharma's stock closed at $21.57 on the previous trading day.
  • The stock traded as low as $20.45 and last traded at $20.59 on Monday.

The players

Urogen Pharma

A clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases.

D. Boral Capital

An equity research firm that has issued a buy rating and $33 price target on Urogen Pharma's stock.

Jefferies Financial Group

An investment bank that has initiated coverage on Urogen Pharma with a buy rating and $40 price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

Urogen Pharma's stock performance and analyst sentiment reflect the ongoing challenges and opportunities facing the company as it works to develop and commercialize its uro-oncology and uro-genital treatments. Investors will likely continue to closely monitor the company's progress and any updates from the analyst community.